Status: Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.
Participants needed: 32
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: HRYZ Biotech Co.Updated: Feb 2, 2024Locations: 1
Eligibility criteria
1. The patient must be willing to sign the informed consent form. [+18]
1. Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it... [+19]